Paper626987
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick RL and 3 others. Cancer Treat Rep, 1978. Cited by 742 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Papers, record 626987. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/626987
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Ovarian Neoplasms | Major topic |
| Ascitic Fluid | |
| Cytarabine | |
| Female | |
| Humans | |
| Injections, Intraperitoneal | |
| Methotrexate | |
| Models, Biological | |
| Tissue Distribution |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00001569 | Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | Background | ClinicalTrials.gov | |
| NCT00004547 | Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy | Background | ClinicalTrials.gov | |
| NCT04885270 | Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer | Background | ClinicalTrials.gov |
Cited by218
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 742 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42449708 | Normothermic Intraperitoneal and Systemic Treatment (NIPS) Using Paclitaxel for Peritoneal Metastases from Gastrointestinal Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449708 | PubMed |
| 42310181 | Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside-a narrative review. | Gastric Cancer | 2026 | https://conductscience.org/library/papers/42310181 | PubMed |
| 42240806 | Pressurised intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases: a scoping review of clinical evidence across emerging indications. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42240806 | PubMed |
| 42166134 | Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2026 | https://conductscience.org/library/papers/42166134 | PubMed |
| 42001371 | Intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, oxaliplatin (FOLFOX) and nivolumab for gastric cancer with peritoneal metastasis: results from the IPLUS Phase II study. | Gastric Cancer | 2026 | https://conductscience.org/library/papers/42001371 | PubMed |
| 41937949 | A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer. | Device | 2026 | https://conductscience.org/library/papers/41937949 | PubMed |
| 41827699 | The New Era of Intraperitoneal Carboplatin in Ovarian Cancer: From Biological Rationale to Clinical Implementation. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41827699 | PubMed |
| 41801509 | Pharmacokinetic and tissue distribution advantages of intraperitoneal oxaliplatin over systemic delivery: a swine model comparison of PIPAC and HPIPAC. | Gastric Cancer | 2026 | https://conductscience.org/library/papers/41801509 | PubMed |
| 41626069 | Considering homologous recombination deficiency status in HIPEC: could molecular testing someday drive "targeted" surgery? | Gynecol Oncol Rep | 2025 | https://conductscience.org/library/papers/41626069 | PubMed |
| 41595106 | Intraperitoneal Chemotherapy Strategies in Pancreatic Ductal Adenocarcinoma: A Systematic Review of Hyperthermic Intraperitoneal Chemotherapy, Normothermic Intraperitoneal Chemotherapy, and Pressurized Intraperitoneal Aerosol Chemotherapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41595106 | PubMed |
| 41580538 | Absolute Bioavailability of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC): Systemic Pharmacokinetics of the CRC-PIPAC-II Trial. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/41580538 | PubMed |
| 41393149 | Tertiary cytoreduction for recurrence of ovarian CANCER patients after intraperitoneal chemotherapy. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41393149 | PubMed |
| 40855029 | Physiological Considerations and Delivery Strategies for Targeting Tumors Through Intraperitoneal Delivery. | Pharm Res | 2025 | https://conductscience.org/library/papers/40855029 | PubMed |
| 40301901 | Postoperative leukopenia after cytoreductive surgery and hypertherm intraperitoneal chemotherapy for colorectal carcinomatosis- causes and implication on outcomes in a population-based study. | World J Surg Oncol | 2025 | https://conductscience.org/library/papers/40301901 | PubMed |
| 40189674 | Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer. | Ann Surg Oncol | 2025 | https://conductscience.org/library/papers/40189674 | PubMed |
| 40016614 | Educational Review: Updates on Therapeutic Strategies for Gastric Cancer with Peritoneal Metastasis. | Ann Surg Oncol | 2025 | https://conductscience.org/library/papers/40016614 | PubMed |
| 39888579 | Innovative landscapes in intraperitoneal therapy of ovarian cancer. | Drug Deliv Transl Res | 2025 | https://conductscience.org/library/papers/39888579 | PubMed |
| 39439460 | Side-Effects on the Renal function of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. | Int J Med Sci | 2024 | https://conductscience.org/library/papers/39439460 | PubMed |
| 39199611 | Optimizing Timing of Intraperitoneal Chemotherapy to Enhance Intravenous Carboplatin Concentration. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39199611 | PubMed |
| 38429574 | Hyperthermic pressurized intraperitoneal aerosol drug delivery system in a large animal model: a feasibility and safety study. | Surg Endosc | 2024 | https://conductscience.org/library/papers/38429574 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/626987
GET https://conductscience.org/api/papers/v1/626987/cited_by?page=2